Isabel Blancas - Publications

Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.

Journal: Frontiers in immunology

Published: April 13, 2026

Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.

Journal: Breast cancer research : BCR

Published: March 19, 2026

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: March 11, 2026

The Early Safety Signal of Sacituzumab Govitecan-Related Toxicity and the UGT1A1*28 Genotype in Metastatic Breast Cancer: A Real-World Preliminary Report.

Journal: Journal of clinical medicine

Published: January 11, 2026

A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 19, 2025

Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 14, 2025

Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 25, 2025

Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.

Journal: Journal of personalized medicine

Published: April 21, 2025

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

Journal: EClinicalMedicine

Published: March 06, 2025

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.

Journal: Future oncology (London, England)

Published: February 28, 2025

Signature-based repurposed drugs resemble the inhibition of TGFβ-induced NDRG1 as potential therapeutics for triple-negative breast cancer.

Journal: International journal of biological sciences

Published: February 22, 2025

Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review.

Journal: Pharmaceutics

Published: January 30, 2025